Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS et al. Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.
CD117 (KIT) Is A Useful Marker in The Diagnosis of Plasmablastic Plasma Cell Myeloma.
Marks E et al. Histopathology. 2017 Feb 22. doi: 10.1111/his.13196. [Epub ahead of print].
In vivo confocal microscopy of multiple myeloma associated crystalline keratopathy.
Busch C et al. Am J Hematol. 2017 Feb 21. doi: 10.1002/ajh.24692. [Epub ahead of print].
Human Allergen-Specific IgG Subclass Antibodies Measured Using ImmunoCAP Technology.
Movérare R et al. Int Arch Allergy Immunol. 2017 Feb 21;172(1):1-10. doi: 10.1159/000455098. [Epub ahead of print].
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
Bailly C et al. Int J Mol Sci. 2017 Feb 18;18(2). pii: E445. doi: 10.3390/ijms18020445.
Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma.
Ippolito D et al. Br J Haematol. 2017 Feb 24. doi: 10.1111/bjh.14545. [Epub ahead of print].
Association between osteogenesis and inflammation during the progression of calcified plaque as evaluated by combined 18F-NaF and 18F-FDG PET/CT.
Li X et al. J Nucl Med. 2017 Feb 23. pii: jnumed.116.182790. doi: 10.2967/jnumed.116.182790. [Epub ahead of print].
Prognostic role of circulating exosomal miRNAs in multiple myeloma.
Manier S et al. Blood. 2017 Feb 17. pii: blood-2016-09-742296. doi: 10.1182/blood-2016-09-742296. [Epub ahead of print].
Analytical and clinical validation of a novel in-house deep sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Martinez-Lopez J et al. Leukemia. 2017 Feb 17. doi: 10.1038/leu.2017.58. [Epub ahead of print].
Muscle Involvement of Multiple Myeloma Revealed by FDG PET/CT.
Liang M et al. Clin Nucl Med. 2017 Feb 13. doi: 10.1097/RLU.0000000000001564. [Epub ahead of print].
Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.
Oberle A et al. Haematologica. 2017 Feb 9. pii: haematol.2016.161414. doi: 10.3324/haematol.2016.161414. [Epub ahead of print].
Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets.
Xiang T et al. PeerJ. 2017 Jan 31;5:e2831. doi: 10.7717/peerj.2831. eCollection 2017.
Diagnosis of Spinal Lesions Using Heuristic and Pharmacokinetic Parameters Measured by Dynamic Contrast-Enhanced MRI.
Lang N et al. Acad Radiol. 2017 Feb 2. pii: S1076-6332(17)30016-8. doi: 10.1016/j.acra.2016.12.014. [Epub ahead of print].
TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y et al. Oncotarget. 2017 Feb 1. doi: 10.18632/oncotarget.14957. [Epub ahead of print].
A concise revised myeloma comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
Engelhardt M et al. Haematologica. 2017 Feb 2. pii: haematol.2016.162693. doi: 10.3324/haematol.2016.162693. [Epub ahead of print].
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
Poi MJ et al. Mol Carcinog. 2017 Feb 2. doi: 10.1002/mc.22626. [Epub ahead of print].
Dermoscopy of cutaneous involvement by multiple myeloma.
Dika E et al. J Am Acad Dermatol. 2017 Feb;76(2S1):S71-S72. doi: 10.1016/j.jaad.2016.08.003.
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A et al. Am J Hematol. 2017 Mar;92(3):269-278. doi: 10.1002/ajh.24634. Epub 2017 Feb 1.